Earlier in 2026, IDEXX Laboratories integrated SDMA, a key renal biomarker recognized by the International Renal Interest ...

Idexx delivered revenue and EPS growth of 6% and 13% in Q4, but its guidance appears to have caught the market's attention. Looking ahead to 2025, management expects the company to grow sales by 4% to ...

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Asset Fund”. A copy of the letter is available to download here. U.S. equity markets started the ...

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that SDMA, a renal ...

Idexx stock clawed higher Tuesday as the pet-health company delivered better-than-expected first-quarter sales, outmaneuvering — again — weak vet visit numbers.

Healthcare diagnostics equipment manufacturer, Idexx Laboratories (NASDAQ: IDXX), is the global leader in pet care. But here's an interesting tidbit: The company's shares have risen 10,230% since 2000 ...

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company ...

Ratings for IDEXX Laboratories (NASDAQ:IDXX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) is one of the Best Stocks to Buy According to Brasada Capital Management. On July 17, Leerink analyst Daniel Clark lifted the company’s price objective to $600 ...

(Reuters) - IDEXX Laboratories raised its full-year profit and sales forecasts on Tuesday, betting on higher demand for its diagnostic tests and lab services as more pet owners visit veterinary ...

IDEXX Laboratories, Inc. (IDXX)’s share price is up by 2.6% over the past month. Over the past five years, IDEXX has been up 50% in the last five years, which is less than the market return. The last ...